RGEN vs ILMN vs RVTY Stock Comparison

Repligen, Illumina and Revvity Prices as of Oct 23, 2026 Peers: Industry group
RGEN Repligen Corp
$176.93 -4.1% 1M +7.1% 1Y
Market cap
$10.14B
P/E
244.2x
Revenue (TTM)
$785.10M
Div. yield
–
Life Sciences Tools Healthcare
3 wins
ILMN Illumina, Inc.
$269.42 +5.5% 1M +169.5% 1Y
Market cap
$40.91B
P/E
49.6x
Revenue (TTM)
$4.49B
Div. yield
–
Life Sciences Tools Healthcare
5 wins
RVTY Revvity, Inc.
$158.70 +11.7% 1M +62.7% 1Y
Market cap
$17.90B
P/E
75.4x
Revenue (TTM)
$2.91B
Div. yield
0.00%
Life Sciences Tools Healthcare
3 wins

Head to Head

11 decided of 12

Illumina leads on 5 of the 12 questions below (Illumina 5, Revvity 3, Repligen 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionRGENILMNRVTYLeader
Larger companyMarket capitalisation $10.14B $40.91B $17.90B ILMN
Cheaper on earningsLower P/E, profitable companies only 244.2x 49.6x 75.4x ILMN
Cheaper on forward earningsLower price / next fiscal year consensus EPS 91.2x 53.9x 31.1x RVTY
Faster revenue growthRevenue growth, trailing twelve months +16.5% +4.9% +4.1% RGEN
More profitableNet margin, trailing twelve months 5.3% 18.4% 8.2% ILMN
Better return on capitalReturn on invested capital 1.9% 15.1% 3.1% ILMN
Less leveragedLower net debt / EBITDA -1.6x 0.7x 2.8x RGEN
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +7.1% +169.5% +62.7% ILMN
Better 5-year returnAnnualised price return, 5 years -8.4%/yr -7.5%/yr -2.1%/yr RVTY
Less volatileAnnualised volatility, 1 year 46.3% 50.3% 39.9% RVTY
Higher overall scoreMean of the five percentile scores vs peers 66/100 65/100 58/100 RGEN

Percentile Scorecard

RGENILMNRVTY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisRGENILMNRVTY
Valuation 53 #108 of 228 52 #111 of 228 69 #72 of 228
Growth 56 #98 of 222 43 #126 of 222 27 #163 of 222
Profitability 70 #63 of 210 97 #7 of 210 79 #46 of 210
Financial Health 80 #49 of 241 51 #118 of 241 47 #128 of 241
Shareholder Returns 70 #42 of 138 84 #23 of 138 68 #45 of 138
Overall 66 65 58
  • RGEN ranked among 248 companies in Medical Devices and Diagnostics
  • ILMN ranked among 248 companies in Medical Devices and Diagnostics
  • RVTY ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodRGENILMNRVTYSPY
1 month -4.1%+5.5%+11.7% -1.0%
3 months +34.1%+38.8%+43.7% +2.9%
6 months +50.5%+110.7%+82.9% +6.4%
Year to date +8.0%+105.4%+64.0% +11.4%
1 year +7.1%+169.5%+62.7% +13.1%
3 years +26.6%+138.6%+55.8% +79.4%
3 years, per year +8.2%+33.6%+15.9% +21.5%
5 years -35.7%-32.3%-10.0% +67.7%
5 years, per year -8.4%-7.5%-2.1% +10.9%
10 years +504.9%+95.3%+201.2% +255.2%
10 years, per year +19.7%+6.9%+11.7% +13.5%

Risk

MeasureRGENILMNRVTYSPY
Volatility, 1Y 46.3%50.3%39.9% 12.7%
Downside volatility, 1Y 46.9%39.1%35.7% 12.7%
Beta vs S&P 500, 1Y 1.180.801.20 1.00
Return / volatility, 1Y 0.153.371.57 1.03
Max drawdown, 5Y -66.2%-82.9%-59.2% -25.4%
From 52-week high -9.1%-8.3%0.0% -2.5%
52-week high $194.57$293.69$158.70 $779.14
52-week low $102.87$95.03$82.26 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleRGENILMNRVTY
P/E now vs peer median 240.3xmedian 30.7x 49.3xmedian 30.7x 74.5xmedian 30.7x
P/S now vs peer median 12.7xmedian 3.0x 9.1xmedian 3.0x 6.1xmedian 3.0x
EV/EBITDA now vs peer median 60.5xmedian 17.7x 36.0xmedian 17.7x 25.6xmedian 17.7x
P/FCF now vs peer median 89.2xmedian 23.7x 43.7xmedian 23.7x 31.1xmedian 23.7x
P/B now vs peer median 4.7xmedian 2.4x 14.3xmedian 2.4x 2.4xmedian 2.4x
PEG now vs peer median -7.90median 0.96 1.64median 0.96 -2.39median 0.96

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsRGENILMNRVTY
Revenue $785.10M $4.49B $2.91B
Gross profit $422.67M $2.98B $1.60B
Operating income $64.61M $882.00M $358.85M
Net income $41.54M $825.00M $237.55M
Free cash flow $111.97M $931.00M $568.85M
R&D $56.17M $960.00M $215.83M
EPS (diluted) $0.73 $5.39 $2.13
Cash & equivalents $606.78M $1.04B $1.02B
Total debt $551.05M $6.97B $3.21B
Shares (diluted) 56.64M 153.00M 111.63M
Enterprise value $7.03B $35.68B $14.17B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricRGENILMNRVTY
P/E 240.3x 49.3x 74.5x
P/FCF 89.2x 43.7x 31.1x
P/Operating cash flow 74.0x 37.2x 27.7x
P/S 12.7x 9.1x 6.1x
P/B 4.7x 14.3x 2.4x
P/Tangible book 5.7x 16.8x 3.5x
EV/EBITDA 60.5x 36.0x 25.6x
EV/EBIT 150.5x 47.1x 55.4x
EV/Revenue 12.4x 9.2x 6.8x
EV/FCF 86.9x 44.6x 35.0x
EV/Operating cash flow 72.1x 37.9x 31.2x
PEG (3Y EPS CAGR) -7.90 1.64 -2.39

Growth

14 metrics
MetricRGENILMNRVTY
Revenue growth (1Y) 16.5% 4.9% 4.1%
Revenue CAGR (3Y) 3.3% -1.0% 0.9%
Gross profit growth (1Y) 40.6% 4.6% 2.3%
Gross profit CAGR (3Y) 4.2% 2.9% -0.4%
Operating income growth (1Y) 370.8% -31.8% -5.5%
Operating income CAGR (3Y) -21.7% 28.3% -3.7%
Net income growth (1Y) 400.4% -34.4% -16.7%
Net income CAGR (3Y) -30.6% 30.0% -33.8%
EPS growth (1Y) 399.7% -32.7% -12.3%
EPS CAGR (3Y) -30.4% 30.1% -31.2%
Operating cash flow growth (1Y) 2.1% -5.1% 6.2%
Operating cash flow CAGR (3Y) -3.2% 38.1% 86.9%
Free cash flow growth (1Y) 2.8% -9.7% 9.5%
Free cash flow CAGR (3Y) 3.9% 105.0% 64.8%

Profitability

14 metrics
MetricRGENILMNRVTY
Gross margin 53.8% 66.4% 55.0%
EBITDA margin 20.5% 25.7% 26.6%
Operating margin 8.2% 19.6% 12.3%
Pretax margin 6.6% 22.6% 9.0%
Net margin 5.3% 18.4% 8.2%
FCF margin 14.3% 20.7% 19.5%
Operating cash flow margin 17.2% 24.4% 21.9%
Return on equity 2.0% 29.9% 3.3%
Return on assets 1.4% 12.5% 2.0%
Return on invested capital 1.9% 15.1% 3.1%
Return on capital employed 2.3% 17.5% 3.3%
Asset turnover 0.3x 0.7x 0.2x
Cash conversion (OCF / net income) 3.2x 1.3x 2.7x
Stock comp / revenue 4.2% 5.9% 0.8%

Financial Health

11 metrics
MetricRGENILMNRVTY
Debt / assets 18.7% 29.9% 26.6%
Debt / equity 0.3x 0.7x 0.4x
Net debt / EBITDA -1.6x 0.7x 2.8x
Debt / FCF 4.9x 2.1x 5.6x
Liabilities / assets 28.4% 57.3% 40.0%
Equity / assets 71.6% 42.7% 60.0%
Interest coverage 2.9x 8.9x 3.7x
Current ratio 9.1x 1.8x 1.8x
Quick ratio 7.3x 1.2x 1.4x
Cash ratio 6.1x 0.7x 0.8x
Altman Z-score 8.14 7.73 3.36

Shareholder Returns

7 metrics
MetricRGENILMNRVTY
Dividend yield – – 0.2%
Net buyback yield 0.0% 1.2% 2.6%
Shareholder yield 0.0% 1.2% 2.8%
Payout ratio (earnings) – – 13.4%
Payout ratio (FCF) – – 5.6%
Dividend growth (1Y) – – -6.3%
Dividend CAGR (3Y) – – -6.1%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusRGENILMNRVTY
Forward P/E 91.2xFY2026 53.9xFY2026 31.1xFY2026
EPS, next fiscal year $1.94FY2026 $5.00FY2026 $5.10FY2026
EPS growth, next FY +13.5%FY2026 +3.3%FY2026 +0.8%FY2026
EPS growth, the year after +29.4% +25.4% +11.0%
Revenue, next fiscal year $772.56MFY2026 $4.52BFY2026 $2.98BFY2026
Revenue growth, next FY +4.6%FY2026 +4.1%FY2026 +4.0%FY2026
Revenue growth, the year after +35.2% +12.0% -2.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersRGENILMNRVTY
Held by institutions 100.0% 100.0% 100.0%
Institutions holding 482 933 545
Change in shares held, QoQ +1.2% +0.0% -1.3%
Institutions buying 272 463 301
Institutions selling 141 330 161
Buyers to sellers 1.93 1.40 1.87

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

RGENILMNRVTY
RGEN 1.00 0.42 0.60
ILMN 0.42 1.00 0.51
RVTY 0.60 0.51 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, RGEN, ILMN and RVTY?

Illumina (ILMN) is the largest by market capitalisation: Repligen (RGEN) $10.14B, Illumina (ILMN) $40.91B, Revvity (RVTY) $17.90B.

Which stock is cheaper, RGEN, ILMN and RVTY?

Illumina (ILMN) trades on the lowest price-to-earnings ratio (Repligen (RGEN) 244.2x, Illumina (ILMN) 49.6x, Revvity (RVTY) 75.4x). On next year's consensus earnings, Revvity (RVTY) is cheapest (Repligen (RGEN) 91.2x, Illumina (ILMN) 53.9x, Revvity (RVTY) 31.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Repligen (RGEN) grew revenue fastest over the trailing twelve months: Repligen (RGEN) +16.5%, Illumina (ILMN) +4.9%, Revvity (RVTY) +4.1%.

Which company is more profitable?

Illumina (ILMN) has the highest net margin (Repligen (RGEN) 5.3%, Illumina (ILMN) 18.4%, Revvity (RVTY) 8.2%). On return on invested capital, Illumina (ILMN) leads (Repligen (RGEN) 1.9%, Illumina (ILMN) 15.1%, Revvity (RVTY) 3.1%).

Which stock has performed better?

Over the past year Illumina (ILMN) returned the most: Repligen (RGEN) +7.1%, Illumina (ILMN) +169.5%, Revvity (RVTY) +62.7%. Over five years, Revvity (RVTY) compounded fastest (Repligen (RGEN) -8.4%/yr, Illumina (ILMN) -7.5%/yr, Revvity (RVTY) -2.1%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Repligen (RGEN) 0.00%, Illumina (ILMN) 0.00%, Revvity (RVTY) 0.00%. Repligen (RGEN) and Illumina (ILMN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Revvity (RVTY) has been the steadiest (Repligen (RGEN) 46.3%, Illumina (ILMN) 50.3%, Revvity (RVTY) 39.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, RGEN, ILMN and RVTY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Illumina (ILMN) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.